This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.
Off-market insider buying at Sernova Biotherapeutics (SVA)
Steven Sangha, a Director, acquired 10,000,000 Common Shares on a direct ownership basis at a price of $0.150 through a prospectus or prospectus exempt offering on April 14th, 2026. The insider also acquired 10,000,000 Warrants with an exercise price of $0.250 for 36 months. This represents a $1,500,000 investment into the company's shares and an account share holdings change of 76.7%.
Sernova Biotherapeutics is in the Medical Equipment, Supplies & Distribution Sub Industry Group under the Healthcare Sector.
Let the insiders guide you to opportunity at Canadianinsider.com.
This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.
